Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Prostate Cancer

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 253 articles:
HTML format



Single Articles


    January 2020
  1. PICKLES K, Kazda L, Barratt A, McGeechan K, et al
    Evaluating two decision aids for Australian men supporting informed decisions about prostate cancer screening: A randomised controlled trial.
    PLoS One. 2020;15:e0227304.
    PubMed     Abstract available


  2. THOMSEN FB, Westerberg M, Garmo H, Robinson D, et al
    Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study.
    PLoS One. 2020;15:e0228447.
    PubMed     Abstract available


  3. NAGAYA N, Nagata M, Lu Y, Kanayama M, et al
    Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.
    PLoS One. 2020;15:e0226219.
    PubMed     Abstract available


  4. LUO Z, Farnham PJ
    Genome-wide analysis of HOXC4 and HOXC6 regulated genes and binding sites in prostate cancer cells.
    PLoS One. 2020;15:e0228590.
    PubMed     Abstract available


  5. LUCAS AR, Bitting RL, Fanning J, Isom S, et al
    Trajectories in muscular strength and physical function among men with and without prostate cancer in the health aging and body composition study.
    PLoS One. 2020;15:e0228773.
    PubMed     Abstract available


  6. LIU JM, Liu YP, Chuang HC, Wu CT, et al
    Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders.
    PLoS One. 2020;15:e0229263.
    PubMed     Abstract available


  7. MEHTALA J, Zong J, Vassilev Z, Brobert G, et al
    Overall survival and second primary malignancies in men with metastatic prostate cancer.
    PLoS One. 2020;15:e0227552.
    PubMed     Abstract available


  8. BEKSISA J, Getinet T, Tanie S, Diribi J, et al
    Survival and prognostic determinants of prostate cancer patients in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A retrospective cohort study.
    PLoS One. 2020;15:e0229854.
    PubMed     Abstract available


  9. WANG Z, Deng T, Long X, Lin X, et al
    Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy.
    PLoS One. 2020;15:e0229754.
    PubMed     Abstract available


  10. ADIKARI A, de Silva D, Ranasinghe WKB, Bandaragoda T, et al
    Can online support groups address psychological morbidity of cancer patients? An artificial intelligence based investigation of prostate cancer trajectories.
    PLoS One. 2020;15:e0229361.
    PubMed     Abstract available


  11. ZOU Y, Tang F, Talbert JC, Ng CM, et al
    Using medical claims database to develop a population disease progression model for leuprorelin-treated subjects with hormone-sensitive prostate cancer.
    PLoS One. 2020;15:e0230571.
    PubMed     Abstract available


  12. JAVAID S, Saad SM, Zafar H, Malik R, et al
    Thymidine phosphorylase and prostrate cancer cell proliferation inhibitory activities of synthetic 4-hydroxybenzohydrazides: In vitro, kinetic, and in silico studies.
    PLoS One. 2020;15:e0227549.
    PubMed     Abstract available


  13. STEINER B, Ferrucci LM, Mirabello L, Lan Q, et al
    Association between coffee drinking and telomere length in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    PLoS One. 2020;15:e0226972.
    PubMed     Abstract available


  14. ULYTE A, Wei W, Dressel H, Gruebner O, et al
    Variation of colorectal, breast and prostate cancer screening activity in Switzerland: Influence of insurance, policy and guidelines.
    PLoS One. 2020;15:e0231409.
    PubMed     Abstract available


  15. DALY C, Logan B, Breeyear J, Whitaker K, et al
    Tks5 SH3 domains exhibit differential effects on invadopodia development.
    PLoS One. 2020;15:e0227855.
    PubMed     Abstract available


  16. HEO JE, Lee JS, Goh HJ, Jang WS, et al
    Urethral realignment with maximal urethral length and bladder neck preservation in robot-assisted radical prostatectomy: Urinary continence recovery.
    PLoS One. 2020;15:e0227744.
    PubMed     Abstract available


  17. MEDHIN LB, Achila OO, Syum BE, Gebremichael KH, et al
    Incidence of prostate cancer in Eritrea: Data from the National Health Laboratory, Orotta Referral Hospital and Sembel Hospital 2011-2018.
    PLoS One. 2020;15:e0232091.
    PubMed     Abstract available


  18. SINGH S, McDonald JT, Ilie G, Adisesh A, et al
    An examination of the association between lifetime history of prostate and pancreatic cancer diagnosis and occupation in a population sample of Canadians.
    PLoS One. 2020;15:e0227622.
    PubMed     Abstract available



  19. Retraction: Prostate Cancer Cell Lines under Hypoxia Exhibit Greater Stem-Like Properties.
    PLoS One. 2020;15:e0233203.
    PubMed    


  20. MURAKAMI Y, Magome T, Matsumoto K, Sato T, et al
    Fully automated dose prediction using generative adversarial networks in prostate cancer patients.
    PLoS One. 2020;15:e0232697.
    PubMed     Abstract available


  21. NGO D, Baumgartner R, Mt-Isa S, Feng D, et al
    Bayesian credible subgroup identification for treatment effectiveness in time-to-event data.
    PLoS One. 2020;15:e0229336.
    PubMed     Abstract available


  22. BRASIL DA COSTA FH, Lewis MS, Truong A, Carson DD, et al
    SULF1 suppresses Wnt3A-driven growth of bone metastatic prostate cancer in perlecan-modified 3D cancer-stroma-macrophage triculture models.
    PLoS One. 2020;15:e0230354.
    PubMed     Abstract available


  23. CHAURASIYA S, Widmann S, Botero C, Lin CY, et al
    Estrogen receptor beta exerts tumor suppressive effects in prostate cancer through repression of androgen receptor activity.
    PLoS One. 2020;15:e0226057.
    PubMed     Abstract available


  24. MACAGNO A, Athanasiou A, Wittig A, Huber R, et al
    Analytical performance of thrombospondin-1 and cathepsin D immunoassays part of a novel CE-IVD marked test as an aid in the diagnosis of prostate cancer.
    PLoS One. 2020;15:e0233442.
    PubMed     Abstract available


  25. GRAHAM LS, Montgomery B, Cheng HH, Yu EY, et al
    Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.
    PLoS One. 2020;15:e0233260.
    PubMed     Abstract available


  26. RIKKERT LG, de Rond L, van Dam A, van Leeuwen TG, et al
    Detection of extracellular vesicles in plasma and urine of prostate cancer patients by flow cytometry and surface plasmon resonance imaging.
    PLoS One. 2020;15:e0233443.
    PubMed     Abstract available


  27. SENNOUNE SR, Nelius T, Jarvis C, Pruitt K, et al
    The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells.
    PLoS One. 2020;15:e0234078.
    PubMed     Abstract available


  28. CHEN MM, Jahn JL, Barber JR, Han M, et al
    Clinical stage provides useful prognostic information even after pathological stage is known for prostate cancer in the PSA era.
    PLoS One. 2020;15:e0234391.
    PubMed     Abstract available


  29. HUSAINI Y, Tsai VW, Manandhar R, Zhang HP, et al
    Growth differentiation factor-15 slows the growth of murine prostate cancer by stimulating tumor immunity.
    PLoS One. 2020;15:e0233846.
    PubMed     Abstract available


  30. SHIN D, Shim SR, Kim CH
    Changes in Beck Depression Inventory scores in prostate cancer patients undergoing androgen deprivation therapy or prostatectomy.
    PLoS One. 2020;15:e0234264.
    PubMed     Abstract available


  31. PACKEISER EM, Hewicker-Trautwein M, Thiemeyer H, Mohr A, et al
    Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis.
    PLoS One. 2020;15:e0230272.
    PubMed     Abstract available


  32. SILTARI A, Murtola TJ, Talala K, Taari K, et al
    Antihypertensive drug use and prostate cancer-specific mortality in Finnish men.
    PLoS One. 2020;15:e0234269.
    PubMed     Abstract available


  33. WU YT, Chiang PH
    Cohort study of high-intensity focused ultrasound in the treatment of localised prostate cancer treatment: Medium-term results from a single centre.
    PLoS One. 2020;15:e0236026.
    PubMed     Abstract available


  34. RHO MJ, Park J, Moon HW, Lee C, et al
    Dr. Answer AI for prostate cancer: Clinical outcome prediction model and service.
    PLoS One. 2020;15:e0236553.
    PubMed     Abstract available


  35. ARIK A, Dodd E, Streftaris G
    Cancer morbidity trends and regional differences in England-A Bayesian analysis.
    PLoS One. 2020;15:e0232844.
    PubMed     Abstract available


  36. DAOUK R, Bahmad HF, Saleh E, Monzer A, et al
    Genome-wide gene expression analysis of a murine model of prostate cancer progression: Deciphering the roles of IL-6 and p38 MAPK as potential therapeutic targets.
    PLoS One. 2020;15:e0237442.
    PubMed     Abstract available


  37. LYNCH SM, Handorf E, Sorice KA, Blackman E, et al
    The effect of neighborhood social environment on prostate cancer development in black and white men at high risk for prostate cancer.
    PLoS One. 2020;15:e0237332.
    PubMed     Abstract available


  38. ERB HHH, Bodenbender J, Handle F, Diehl T, et al
    Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer.
    PLoS One. 2020;15:e0237248.
    PubMed     Abstract available


  39. BOU-DARGHAM MJ, Sang QA
    Secretome analysis reveals upregulated granzyme B in human androgen-repressed prostate cancer cells with mesenchymal and invasive phenotype.
    PLoS One. 2020;15:e0237222.
    PubMed     Abstract available


  40. PAPANDRIANOS N, Papageorgiou E, Anagnostis A, Papageorgiou K, et al
    Bone metastasis classification using whole body images from prostate cancer patients based on convolutional neural networks application.
    PLoS One. 2020;15:e0237213.
    PubMed     Abstract available


  41. YAMADA Y, Teshima T, Fujimura T, Sato Y, et al
    Comparison of perioperative outcomes in elderly (age >== 75 years) vs. younger men undergoing robot-assisted radical prostatectomy.
    PLoS One. 2020;15:e0234113.
    PubMed     Abstract available


  42. SANTOS-SANCHEZ V, Cordoba-Dona JA, Viciana F, Escolar-Pujolar A, et al
    Geographical variations in cancer mortality and social inequalities in southern Spain (Andalusia). 2002-2013.
    PLoS One. 2020;15:e0233397.
    PubMed     Abstract available


  43. STROOMBERG HV, Jorgensen A, Brasso K, Nielsen JE, et al
    Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients.
    PLoS One. 2020;15:e0238814.
    PubMed     Abstract available


  44. GROARKE A, Curtis R, Skelton J, Groarke JM, et al
    Quality of life and adjustment in men with prostate cancer: Interplay of stress, threat and resilience.
    PLoS One. 2020;15:e0239469.
    PubMed     Abstract available


  45. ALADWANI M, Lophatananon A, Robinson F, Rahman A, et al
    Relationship of self-reported body size and shape with risk for prostate cancer: A UK case-control study.
    PLoS One. 2020;15:e0238928.
    PubMed     Abstract available


  46. MISHRA MV, Thayer WM, Janssen E, Hoppe B, et al
    Patient preferences for reducing bowel adverse events following prostate radiotherapy.
    PLoS One. 2020;15:e0235616.
    PubMed     Abstract available


    January 2019
  47. RODRIGUEZ-SANCHEZ L, Fernandez-Navarro P, Lopez-Abente G, Nunez O, et al
    Different spatial pattern of municipal prostate cancer mortality in younger men in Spain.
    PLoS One. 2019;14:e0210980.
    PubMed     Abstract available


  48. GOUPY F, Supiot S, Pasquier D, Latorzeff I, et al
    Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b): A multicentric retrospective analysis.
    PLoS One. 2019;14:e0210514.
    PubMed     Abstract available


  49. JEGERLEHNER S, Chiolero A, Aujesky D, Rodondi N, et al
    Recent incidence and surgery trends for prostate cancer: Towards an attenuation of overdiagnosis and overtreatment?
    PLoS One. 2019;14:e0210434.
    PubMed     Abstract available


  50. KARLSSON A, Jauhiainen A, Gulati R, Eklund M, et al
    A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data.
    PLoS One. 2019;14:e0211918.
    PubMed     Abstract available


  51. LAI CC, Huang PH, Wang FN, Shen SH, et al
    Histogram analysis of prostate cancer on dynamic contrast-enhanced magnetic resonance imaging: A preliminary study emphasizing on zonal difference.
    PLoS One. 2019;14:e0212092.
    PubMed     Abstract available


  52. ANTICO M, Prinsen P, Cellini F, Fracassi A, et al
    Real-time adaptive planning method for radiotherapy treatment delivery for prostate cancer patients, based on a library of plans accounting for possible anatomy configuration changes.
    PLoS One. 2019;14:e0213002.
    PubMed     Abstract available


  53. TAKAKUSAGI Y, Kawamura H, Okamoto M, Kaminuma T, et al
    Long-term outcome of hypofractionated intensity-modulated radiotherapy using TomoTherapy for localized prostate cancer: A retrospective study.
    PLoS One. 2019;14:e0211370.
    PubMed     Abstract available


  54. KANNAN A, Kirkman M, Ruseckaite R, Evans SM, et al
    Prostate cancer awareness, case-finding, and early diagnosis: Interviews with undiagnosed men in Australia.
    PLoS One. 2019;14:e0211539.
    PubMed     Abstract available


  55. LEUNG YK, Chan QK, Ng CF, Ma FM, et al
    Correction: Hsa-miRNA-765 as a Key Mediator for Inhibiting Growth, Migration and Invasion in Fulvestrant-Treated Prostate Cancer.
    PLoS One. 2019;14:e0214184.
    PubMed     Abstract available


  56. MARZORATI C, Monzani D, Mazzocco K, Pavan F, et al
    Predicting trajectories of recovery in prostate cancer patients undergone Robot-Assisted Radical Prostatectomy (RARP).
    PLoS One. 2019;14:e0214682.
    PubMed     Abstract available


  57. SEKHAR KR, Wang J, Freeman ML, Kirschner AN, et al
    Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway.
    PLoS One. 2019;14:e0214670.
    PubMed     Abstract available


  58. SONG C, Byun SJ, Kim YS, Ahn H, et al
    Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: A propensity score matching analysis.
    PLoS One. 2019;14:e0215057.
    PubMed     Abstract available


  59. BRYZGUNOVA OE, Zaporozhchenko IA, Lekchnov EA, Amelina EV, et al
    Data analysis algorithm for the development of extracellular miRNA-based diagnostic systems for prostate cancer.
    PLoS One. 2019;14:e0215003.
    PubMed     Abstract available


  60. DERYCKE MS, Larson MC, Nair AA, McDonnell SK, et al
    An expanded variant list and assembly annotation identifies multiple novel coding and noncoding genes for prostate cancer risk using a normal prostate tissue eQTL data set.
    PLoS One. 2019;14:e0214588.
    PubMed     Abstract available


  61. MATZKIN H, Chen J, Agai R, Ziv-Baran T, et al
    Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification.
    PLoS One. 2019;14:e0215582.
    PubMed     Abstract available


  62. GUENTHER E, Klein N, Zapf S, Weil S, et al
    Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments.
    PLoS One. 2019;14:e0215093.
    PubMed     Abstract available


  63. REDDY V, Iskander A, Hwang C, Divine G, et al
    Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell death.
    PLoS One. 2019;14:e0211090.
    PubMed     Abstract available


  64. ARMSTRONG AJ, Gupta S, Healy P, Kemeny G, et al
    Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
    PLoS One. 2019;14:e0216934.
    PubMed     Abstract available


  65. KARUNASINGHE N, Symes E, Gamage A, Wang A, et al
    Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand.
    PLoS One. 2019;14:e0217373.
    PubMed     Abstract available


  66. PALSDOTTIR T, Nordstrom T, Aly M, Lindberg J, et al
    Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study.
    PLoS One. 2019;14:e0218280.
    PubMed     Abstract available


  67. ZECHMANN S, Di Gangi S, Kaplan V, Meier R, et al
    Time trends in prostate cancer screening in Swiss primary care (2010 to 2017) - A retrospective study.
    PLoS One. 2019;14:e0217879.
    PubMed     Abstract available


  68. JARRARD WE, Schultz A, Etheridge T, Damodaran S, et al
    Screening of urine identifies PLA2G16 as a field defect methylation biomarker for prostate cancer detection.
    PLoS One. 2019;14:e0218950.
    PubMed     Abstract available


  69. TOIVONEN J, Montoya Perez I, Movahedi P, Merisaari H, et al
    Radiomics and machine learning of multisequence multiparametric prostate MRI: Towards improved non-invasive prostate cancer characterization.
    PLoS One. 2019;14:e0217702.
    PubMed     Abstract available


  70. BRATTON BA, Maly IV, Hofmann WA
    Effect of polyunsaturated fatty acids on proliferation and survival of prostate cancer cells.
    PLoS One. 2019;14:e0219822.
    PubMed     Abstract available


  71. BURNELL SEA, Spencer-Harty S, Howarth S, Bodger O, et al
    Utilisation of the STEAP protein family in a diagnostic setting may provide a more comprehensive prognosis of prostate cancer.
    PLoS One. 2019;14:e0220456.
    PubMed     Abstract available


  72. BISHOP MR, Huskey ALW, Hetzel J, Merner ND, et al
    A research-based gene panel to investigate breast, ovarian and prostate cancer genetic risk.
    PLoS One. 2019;14:e0220929.
    PubMed     Abstract available


  73. XU L, Lee JR, Hao S, Ling XB, et al
    Improved detection of prostate cancer using a magneto-nanosensor assay for serum circulating autoantibodies.
    PLoS One. 2019;14:e0221051.
    PubMed     Abstract available


  74. JEON JM, Kwon OK, Na AY, Sung EJ, et al
    Secretome profiling of PC3/nKR cells, a novel highly migrating prostate cancer subline derived from PC3 cells.
    PLoS One. 2019;14:e0220807.
    PubMed     Abstract available


  75. RADTKE JP, Giganti F, Wiesenfarth M, Stabile A, et al
    Prediction of significant prostate cancer in biopsy-naive men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS.
    PLoS One. 2019;14:e0221350.
    PubMed     Abstract available


  76. JEON JM, Kwon OK, Na AY, Sung EJ, et al
    Correction: Secretome profiling of PC3/nKR cells, a novel highly migrating prostate cancer subline derived from PC3 cells.
    PLoS One. 2019;14:e0222693.
    PubMed     Abstract available


  77. ZHANG W, Hu C, Wang X, Bai S, et al
    Role of GDF15 in methylseleninic acid-mediated inhibition of cell proliferation and induction of apoptosis in prostate cancer cells.
    PLoS One. 2019;14:e0222812.
    PubMed     Abstract available


  78. LEE GT, Rosenfeld JA, Kim WT, Kwon YS, et al
    TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer.
    PLoS One. 2019;14:e0213488.
    PubMed     Abstract available



  79. Expression of Concern: Resveratrol Enhances Antitumor Activity of TRAIL in Prostate Cancer Xenografts through Activation of FOXO Transcription Factor.
    PLoS One. 2019;14:e0223138.
    PubMed    


  80. HUGHES S, Egger S, Carle C, Smith DP, et al
    Factors associated with the use of diet and the use of exercise for prostate cancer by long-term survivors.
    PLoS One. 2019;14:e0223407.
    PubMed     Abstract available


  81. KOZIKOWSKI M, Malewski W, Michalak W, Dobruch J, et al
    Clinical utility of MRI in the decision-making process before radical prostatectomy: Systematic review and meta-analysis.
    PLoS One. 2019;14:e0210194.
    PubMed     Abstract available


  82. TEOH JYC, Hirai HW, Ho JMW, Chan FCH, et al
    Global incidence of prostate cancer in developing and developed countries with changing age structures.
    PLoS One. 2019;14:e0221775.
    PubMed     Abstract available


  83. LEE DH, Yu EJ, Aldahl J, Yang J, et al
    Deletion of the p16INK4a tumor suppressor and expression of the androgen receptor induce sarcomatoid carcinomas with signet ring cells in the mouse prostate.
    PLoS One. 2019;14:e0211153.
    PubMed     Abstract available


  84. LIU X, Wiersma RD
    Optimization based trajectory planning for real-time 6DoF robotic patient motion compensation systems.
    PLoS One. 2019;14:e0210385.
    PubMed     Abstract available


  85. BUGLIONE M, Noale M, Bruni A, Antonelli A, et al
    Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR).
    PLoS One. 2019;14:e0224151.
    PubMed     Abstract available


  86. MAAHS L, Sanchez BE, Gupta N, Van Harn M, et al
    Class III beta-tubulin expression as a predictor of docetaxel-resistance in metastatic castration-resistant prostate cancer.
    PLoS One. 2019;14:e0222510.
    PubMed     Abstract available


  87. BYUN SS, Lee M, Hong SK, Lee H, et al
    Elevated Ki-67 (MIB-1) expression as an independent predictor for unfavorable pathologic outcomes and biochemical recurrence after radical prostatectomy in patients with localized prostate cancer: A propensity score matched study.
    PLoS One. 2019;14:e0224671.
    PubMed     Abstract available


  88. YOU D, Kim Y, Jang MJ, Lee C, et al
    Correction: KML001 Induces Apoptosis and Autophagic Cell Death in Prostate Cancer Cells via Oxidative Stress Pathway.
    PLoS One. 2019;14:e0225087.
    PubMed     Abstract available


  89. VERMA S, Pandey M, Shukla GC, Singh V, et al
    Integrated analysis of miRNA landscape and cellular networking pathways in stage-specific prostate cancer.
    PLoS One. 2019;14:e0224071.
    PubMed     Abstract available


  90. SEAMAN AT, Taylor KL, Davis K, Nepple KG, et al
    Why men with a low-risk prostate cancer select and stay on active surveillance: A qualitative study.
    PLoS One. 2019;14:e0225134.
    PubMed     Abstract available


  91. ZHENG S, Jiang S, Chen Z, Huang Z, et al
    The roles of MRI-based prostate volume and associated zone-adjusted prostate-specific antigen concentrations in predicting prostate cancer and high-risk prostate cancer.
    PLoS One. 2019;14:e0218645.
    PubMed     Abstract available


  92. WETTERAUER C, Winkel DJ, Federer-Gsponer JR, Halla A, et al
    Structured reporting of prostate magnetic resonance imaging has the potential to improve interdisciplinary communication.
    PLoS One. 2019;14:e0212444.
    PubMed     Abstract available


  93. COSMA I, Tennstedt-Schenk C, Winzler S, Psychogios MN, et al
    The role of gadolinium in magnetic resonance imaging for early prostate cancer diagnosis: A diagnostic accuracy study.
    PLoS One. 2019;14:e0227031.
    PubMed     Abstract available


  94. BEER L, Polanec SH, Baltzer PAT, Schatzl G, et al
    4D perfusion CT of prostate cancer for image-guided radiotherapy planning: A proof of concept study.
    PLoS One. 2019;14:e0225673.
    PubMed     Abstract available


  95. ZHANG H, Gordon R, Li W, Yang X, et al
    Genistein treatment duration effects biomarkers of cell motility in human prostate.
    PLoS One. 2019;14:e0214078.
    PubMed     Abstract available


  96. BOUTTELL J, Teoh J, Chiu PK, Chan KS, et al
    Economic evaluation of the introduction of the Prostate Health Index as a rule-out test to avoid unnecessary biopsies in men with prostate specific antigen levels of 4-10 in Hong Kong.
    PLoS One. 2019;14:e0215279.
    PubMed     Abstract available


  97. DURST MA, Ratia K, Lavie A
    Identifying small molecule probes of ENTPD5 through high throughput screening.
    PLoS One. 2019;14:e0210305.
    PubMed     Abstract available


  98. SIROHI D, Devine P, Grenert JP, van Ziffle J, et al
    TP53 structural variants in metastatic prostatic carcinoma.
    PLoS One. 2019;14:e0218618.
    PubMed     Abstract available


  99. RABIN-COURT A, Rodrigues MR, Zhang XM, Perry RJ, et al
    Obesity-associated, but not obesity-independent, tumors respond to insulin by increasing mitochondrial glucose oxidation.
    PLoS One. 2019;14:e0218126.
    PubMed     Abstract available


  100. SZCZUREK L, Juszkat R, Szczurek J, Turek I, et al
    Pre-treatment 2D and 3D dosimetric verification of volumetric arc therapy. A correlation study between gamma index passing rate and clinical dose volume histogram.
    PLoS One. 2019;14:e0221086.
    PubMed     Abstract available


  101. LU S, Dong Z
    Additive effects of a small molecular PCNA inhibitor PCNA-I1S and DNA damaging agents on growth inhibition and DNA damage in prostate and lung cancer cells.
    PLoS One. 2019;14:e0223894.
    PubMed     Abstract available


  102. HONG Y, Lee S, Won S
    The preventive effect of metformin on progression of benign prostate hyperplasia: A nationwide population-based cohort study in Korea.
    PLoS One. 2019;14:e0219394.
    PubMed     Abstract available


  103. TAN JWY, Murashov MD, Rosania GR, Wang X, et al
    Photoacoustic imaging of clofazimine hydrochloride nanoparticle accumulation in cancerous vs normal prostates.
    PLoS One. 2019;14:e0219655.
    PubMed     Abstract available


  104. KATSOGIANNOU M, Boyer JB, Valdeolivas A, Remy E, et al
    Integrative proteomic and phosphoproteomic profiling of prostate cell lines.
    PLoS One. 2019;14:e0224148.
    PubMed     Abstract available


  105. BECK S, Borutta B, Walter U, Dreier M, et al
    Systematic evaluation of written health information on PSA based screening in Germany.
    PLoS One. 2019;14:e0220745.
    PubMed     Abstract available


  106. PAL G, Ogunwobi OO
    Copy number-based quantification assay for non-invasive detection of PVT1-derived transcripts.
    PLoS One. 2019;14:e0226620.
    PubMed     Abstract available


  107. SU SY, Lee WC
    Age-period-cohort analysis with a constant-relative-variation constraint for an apportionment of period and cohort slopes.
    PLoS One. 2019;14:e0226678.
    PubMed     Abstract available


  108. PATEL DI, Abuchowski K, Bedolla R, Rivas P, et al
    Nexrutine and exercise similarly prevent high grade prostate tumors in transgenic mouse model.
    PLoS One. 2019;14:e0226187.
    PubMed     Abstract available


  109. SHARMA D, Giles A, Hashim A, Yip J, et al
    Ultrasound microbubble potentiated enhancement of hyperthermia-effect in tumours.
    PLoS One. 2019;14:e0226475.
    PubMed     Abstract available


  110. BOOTH N, Rissanen P, Tammela TLJ, Kujala P, et al
    Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
    PLoS One. 2019;14:e0224479.
    PubMed     Abstract available


    January 2018
  111. YANG F, Yu N, Wang H, Zhang C, et al
    Downregulated expression of hepatoma-derived growth factor inhibits migration and invasion of prostate cancer cells by suppressing epithelial-mesenchymal transition and MMP2, MMP9.
    PLoS One. 2018;13:e0190725.
    PubMed     Abstract available


  112. SRIVASTAVA P, Sarma A, Chaturvedi CM
    Targeting DNA repair with PNKP inhibition sensitizes radioresistant prostate cancer cells to high LET radiation.
    PLoS One. 2018;13:e0190516.
    PubMed     Abstract available


  113. BYUN SJ, Kim YS, Ahn H, Kim CS, et al
    Image-guided, whole-pelvic, intensity-modulated radiotherapy for biochemical recurrence following radical prostatectomy in high-risk prostate cancer patients.
    PLoS One. 2018;13:e0190479.
    PubMed     Abstract available


  114. BARAKAT DJ, Suresh R, Barberi T, Pienta KJ, et al
    Absence of myeloid Klf4 reduces prostate cancer growth with pro-atherosclerotic activation of tumor myeloid cells and infiltration of CD8 T cells.
    PLoS One. 2018;13:e0191188.
    PubMed     Abstract available


  115. HAYES AR, Brungs D, Pavlakis N
    Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0191455.
    PubMed     Abstract available


  116. KORONOWICZ AA, Drozdowska M, Wielgos B, Piasna-Slupecka E, et al
    The effect of "NutramilTM Complex," food for special medical purpose, on breast and prostate carcinoma cells.
    PLoS One. 2018;13:e0192860.
    PubMed     Abstract available


  117. GILLEBERT Q, Huchet V, Rousseau C, Cochet A, et al
    18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study.
    PLoS One. 2018;13:e0191487.
    PubMed     Abstract available


  118. JAYARAMAN A, Kumar P, Marin S, de Atauri P, et al
    Untargeted metabolomics reveals distinct metabolic reprogramming in endothelial cells co-cultured with CSC and non-CSC prostate cancer cell subpopulations.
    PLoS One. 2018;13:e0192175.
    PubMed     Abstract available


  119. EGGER S, Hughes S, Smith DP, Chambers S, et al
    Factors associated with the use of complementary and alternative medicines for prostate cancer by long-term survivors.
    PLoS One. 2018;13:e0193686.
    PubMed     Abstract available


  120. SHIN H, Park YH, Kim YG, Lee JY, et al
    Aqueous two-phase system to isolate extracellular vesicles from urine for prostate cancer diagnosis.
    PLoS One. 2018;13:e0194818.
    PubMed     Abstract available


  121. RUSSELL B, Garmo H, Beckmann K, Stattin P, et al
    A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0.
    PLoS One. 2018;13:e0195690.
    PubMed     Abstract available


  122. FRYZEK JP, Reichert H, Summers N, Townes L, et al
    Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen.
    PLoS One. 2018;13:e0195790.
    PubMed     Abstract available


  123. GOINEAU A, Campion L, d'Aillieres B, Vie B, et al
    Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients.
    PLoS One. 2018;13:e0194173.
    PubMed     Abstract available


  124. CAMPBELL DH, Lund ME, Nocon AL, Cozzi PJ, et al
    Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer.
    PLoS One. 2018;13:e0196017.
    PubMed     Abstract available


  125. WALSH DMJ, Groarke AM, Morrison TG, Durkan G, et al
    Measuring a new facet of post traumatic growth: Development of a scale of physical post traumatic growth in men with prostate cancer.
    PLoS One. 2018;13:e0195992.
    PubMed     Abstract available


  126. CHEUNG S, Hamuro Y, Mahlich J, Nakayama M, et al
    Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data.
    PLoS One. 2018;13:e0195789.
    PubMed     Abstract available


  127. SCHWEIZER MT, Haugk K, McKiernan JS, Gulati R, et al
    A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.
    PLoS One. 2018;13:e0198389.
    PubMed     Abstract available


  128. MARU S, Uchino H, Osawa T, Chiba S, et al
    Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy.
    PLoS One. 2018;13:e0197252.
    PubMed     Abstract available


  129. SMITH DP, Calopedos R, Bang A, Yu XQ, et al
    Increased risk of suicide in New South Wales men with prostate cancer: Analysis of linked population-wide data.
    PLoS One. 2018;13:e0198679.
    PubMed     Abstract available


  130. PARK JW, Koh DH, Jang WS, Lee JY, et al
    Age-adjusted Charlson Comorbidity Index as a prognostic factor for radical prostatectomy outcomes of very high-risk prostate cancer patients.
    PLoS One. 2018;13:e0199365.
    PubMed     Abstract available


  131. KARUNASINGHE N, Ambs S, Wang A, Tang W, et al
    Influence of lifestyle and genetic variants in the aldo-keto reductase 1C3 rs12529 polymorphism in high-risk prostate cancer detection variability assessed between US and New Zealand cohorts.
    PLoS One. 2018;13:e0199122.
    PubMed     Abstract available


  132. EBBING J, Jaderling F, Collins JW, Akre O, et al
    Comparison of 3D printed prostate models with standard radiological information to aid understanding of the precise location of prostate cancer: A construct validation study.
    PLoS One. 2018;13:e0199477.
    PubMed     Abstract available


  133. LEE H, Hwang SI, Lee HJ, Byun SS, et al
    Diagnostic performance of diffusion-weighted imaging for prostate cancer: Peripheral zone versus transition zone.
    PLoS One. 2018;13:e0199636.
    PubMed     Abstract available


  134. WALSH TJ, Shores MM, Krakauer CA, Forsberg CW, et al
    Testosterone treatment and the risk of aggressive prostate cancer in men with low testosterone levels.
    PLoS One. 2018;13:e0199194.
    PubMed     Abstract available


  135. FERRARINI A, Forcato C, Buson G, Tononi P, et al
    A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products.
    PLoS One. 2018;13:e0193689.
    PubMed     Abstract available


  136. BOURKE L, Turner R, Greasley R, Sutton E, et al
    A multi-centre investigation of delivering national guidelines on exercise training for men with advanced prostate cancer undergoing androgen deprivation therapy in the UK NHS.
    PLoS One. 2018;13:e0197606.
    PubMed     Abstract available


  137. DANKERT JT, Wiesehofer M, Czyrnik ED, Singer BB, et al
    The deregulation of miR-17/CCND1 axis during neuroendocrine transdifferentiation of LNCaP prostate cancer cells.
    PLoS One. 2018;13:e0200472.
    PubMed     Abstract available


  138. KOITSALU M, Eklund M, Adolfsson J, Sprangers MAG, et al
    Predictors of participation in risk-based prostate cancer screening.
    PLoS One. 2018;13:e0200409.
    PubMed     Abstract available


  139. PRITCHARD AL, Johansson PA, Nathan V, Howlie M, et al
    Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers.
    PLoS One. 2018;13:e0194098.
    PubMed     Abstract available


  140. NAIR-SHALLIKER V, Egger S, Chrzanowska A, Mason R, et al
    Associations between sun sensitive pigmentary genes and serum prostate specific antigen levels.
    PLoS One. 2018;13:e0193893.
    PubMed     Abstract available


  141. SCHAAKE W, van der Schaaf A, van Dijk LV, van den Bergh ACM, et al
    Development of a prediction model for late urinary incontinence, hematuria, pain and voiding frequency among irradiated prostate cancer patients.
    PLoS One. 2018;13:e0197757.
    PubMed     Abstract available


  142. TENTORI K, Pighin S, Divan C, Crupi V, et al
    Mind the gap: Physicians' assessment of patients' importance weights in localized prostate cancer.
    PLoS One. 2018;13:e0200780.
    PubMed     Abstract available


  143. BIALKOWSKA K, Marciniak W, Muszynska M, Baszuk P, et al
    Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population.
    PLoS One. 2018;13:e0201065.
    PubMed     Abstract available


  144. HILLEBRAND AC, Pizzolato LS, Neto BS, Branchini G, et al
    Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer.
    PLoS One. 2018;13:e0200613.
    PubMed     Abstract available


  145. JANSEN RJ, Alexander BH, Hayes RB, Miller AB, et al
    A mathematical model of case-ascertainment bias: Applied to case-control studies nested within a randomized screening trial.
    PLoS One. 2018;13:e0194608.
    PubMed     Abstract available


  146. PUNNEN S, Nahar B, Soodana-Prakash N, Koru-Sengul T, et al
    Optimizing patient's selection for prostate biopsy: A single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer.
    PLoS One. 2018;13:e0201384.
    PubMed     Abstract available


  147. KOIKE Y, Sumida I, Mizuno H, Shiomi H, et al
    Dosimetric impact of intra-fraction prostate motion under a tumour-tracking system in hypofractionated robotic radiosurgery.
    PLoS One. 2018;13:e0195296.
    PubMed     Abstract available


  148. SCHWEIZER MT, Haugk K, McKiernan JS, Gulati R, et al
    Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.
    PLoS One. 2018;13:e0202709.
    PubMed     Abstract available


  149. YE Y, Li SL, Wang SY
    Construction and analysis of mRNA, miRNA, lncRNA, and TF regulatory networks reveal the key genes associated with prostate cancer.
    PLoS One. 2018;13:e0198055.
    PubMed     Abstract available


  150. BRIDGES D, Kawamura H, Kanai T
    Probabilistic dose distribution from interfractional motion in carbon ion radiation therapy for prostate cancer shows rectum sparing with moderate target coverage degradation.
    PLoS One. 2018;13:e0203289.
    PubMed     Abstract available


  151. PENZIAS G, Singanamalli A, Elliott R, Gollamudi J, et al
    Identifying the morphologic basis for radiomic features in distinguishing different Gleason grades of prostate cancer on MRI: Preliminary findings.
    PLoS One. 2018;13:e0200730.
    PubMed     Abstract available


  152. KIM JJ, Kim T, Lee H, Byun SS, et al
    Prediction of unilateral prostate cancer by the combination of transrectal ultrasonography-guided prostate biopsy and multi-parametric magnetic resonance imaging: A real-life experience.
    PLoS One. 2018;13:e0202872.
    PubMed     Abstract available


  153. GUO Y, Wang L, Hu J, Feng D, et al
    Diagnostic performance of choline PET/CT for the detection of bone metastasis in prostate cancer: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0203400.
    PubMed     Abstract available


  154. LIN HW, Lin LF, Chen HC, Liou TH, et al
    Chronic obstructive pulmonary disease with short-acting inhaled pharmacotherapy increases the risk of prostate cancer: A two-stage database approach.
    PLoS One. 2018;13:e0203377.
    PubMed     Abstract available


  155. HASAN D, Gamen E, Abu Tarboush N, Ismail Y, et al
    PKM2 and HIF-1alpha regulation in prostate cancer cell lines.
    PLoS One. 2018;13:e0203745.
    PubMed     Abstract available


  156. MOSES-FYNN E, Tang W, Beyene D, Apprey V, et al
    Correlating blood-based DNA methylation markers and prostate cancer risk in African-American men.
    PLoS One. 2018;13:e0203322.
    PubMed     Abstract available


  157. CHOI YJ, Lee DH, Han KD, Yoon H, et al
    Is nonalcoholic fatty liver disease associated with the development of prostate cancer? A nationwide study with 10,516,985 Korean men.
    PLoS One. 2018;13:e0201308.
    PubMed     Abstract available


  158. MILOSAVLJEVIC V, Haddad Y, Merlos Rodrigo MA, Moulick A, et al
    Correction: The Zinc-Schiff Base-Novicidin Complex as a Potential Prostate Cancer Therapy.
    PLoS One. 2018;13:e0204441.
    PubMed     Abstract available


  159. LEIGHTON X, Bera A, Eidelman O, Bubendorf L, et al
    Tissue microarray analysis delineate potential prognostic role of Annexin A7 in prostate cancer progression.
    PLoS One. 2018;13:e0205837.
    PubMed     Abstract available


  160. WU X, Zhang K, Chen Y, Wang R, et al
    Theoretical and experimental study of dual-fiber laser ablation for prostate cancer.
    PLoS One. 2018;13:e0206065.
    PubMed     Abstract available


  161. BABALYAN K, Sultanov R, Generozov E, Sharova E, et al
    LogLoss-BERAF: An ensemble-based machine learning model for constructing highly accurate diagnostic sets of methylation sites accounting for heterogeneity in prostate cancer.
    PLoS One. 2018;13:e0204371.
    PubMed     Abstract available


  162. ZHANG S, Zheng C, Yao S, Wang Z, et al
    Proteomic analysis of human prostate cancer PC-3M-1E8 cells and PC-3M-2B4 cells of same origin but with different metastatic potential.
    PLoS One. 2018;13:e0206139.
    PubMed     Abstract available


  163. ZHANG X, Lin Y, Xie X, Shen M, et al
    Is acne in adolescence associated with prostate cancer risk? Evidence from a meta-analysis.
    PLoS One. 2018;13:e0206249.
    PubMed     Abstract available


  164. VARNAVA M, Sumida I, Mizuno H, Shiomi H, et al
    A new plan quality objective function for determining optimal collimator combinations in prostate cancer treatment with stereotactic body radiation therapy using CyberKnife.
    PLoS One. 2018;13:e0208086.
    PubMed     Abstract available


  165. CHIU TD, Arai TJ, Campbell Iii J, Jiang SB, et al
    MR-CBCT image-guided system for radiotherapy of orthotopic rat prostate tumors.
    PLoS One. 2018;13:e0198065.
    PubMed     Abstract available


  166. GROCHTDREIS T, Konig HH, Dobruschkin A, von Amsberg G, et al
    Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review.
    PLoS One. 2018;13:e0208063.
    PubMed     Abstract available


  167. HUANG MH, Blackwood J, Godoshian M, Pfalzer L, et al
    Factors associated with self-reported falls, balance or walking difficulty in older survivors of breast, colorectal, lung, or prostate cancer: Results from Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey linkage.
    PLoS One. 2018;13:e0208573.
    PubMed     Abstract available


  168. TINZL M, Chen B, Chen SY, Semenas J, et al
    Correction: Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer.
    PLoS One. 2018;13:e0209544.
    PubMed     Abstract available


  169. PARK JW, Lee JH, Cho HJ, Ha YJ, et al
    Influence of androgen deprivation therapy on serum urate levels in patients with prostate cancer: A retrospective observational study.
    PLoS One. 2018;13:e0209049.
    PubMed     Abstract available


  170. CHUNG DY, Goh HJ, Koh DH, Kim MS, et al
    Clinical significance of multiparametric MRI and PSA density as predictors of residual tumor (pT0) following radical prostatectomy for T1a-T1b (incidental) prostate cancer.
    PLoS One. 2018;13:e0210037.
    PubMed     Abstract available


  171. FONSECA-ALVES CE, Kobayashi PE, Rivera Calderon LG, Felisbino SL, et al
    Immunohistochemical panel to characterize canine prostate carcinomas according to aberrant p63 expression.
    PLoS One. 2018;13:e0199173.
    PubMed     Abstract available


  172. GUPTA S, Silveira DA, Mombach JCM
    Modeling the role of microRNA-449a in the regulation of the G2/M cell cycle checkpoint in prostate LNCaP cells under ionizing radiation.
    PLoS One. 2018;13:e0200768.
    PubMed     Abstract available


  173. ARAS O, Pearce G, Watkins AJ, Nurili F, et al
    An in-vivo pilot study into the effects of FDG-mNP in cancer in mice.
    PLoS One. 2018;13:e0202482.
    PubMed     Abstract available


  174. GOMEZ-ACEBO I, Dierssen-Sotos T, Palazuelos C, Fernandez-Navarro P, et al
    Pigmentation phototype and prostate and breast cancer in a select Spanish population-A Mendelian randomization analysis in the MCC-Spain study.
    PLoS One. 2018;13:e0201750.
    PubMed     Abstract available


  175. HERNANDEZ J, Gelfond J, Goros M, Liss MA, et al
    The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial.
    PLoS One. 2018;13:e0204823.
    PubMed     Abstract available


  176. LU DL, Ren ZJ, Zhang Q, Ren PW, et al
    Meta-analysis of the association between the inflammatory potential of diet and urologic cancer risk.
    PLoS One. 2018;13:e0204845.
    PubMed     Abstract available


  177. BURTON LJ, Hawsawi O, Loyd Q, Henderson V, et al
    Association of Epithelial Mesenchymal Transition with prostate and breast health disparities.
    PLoS One. 2018;13:e0203855.
    PubMed     Abstract available


  178. DE SILVA D, Ranasinghe W, Bandaragoda T, Adikari A, et al
    Machine learning to support social media empowered patients in cancer care and cancer treatment decisions.
    PLoS One. 2018;13:e0205855.
    PubMed     Abstract available


  179. BALLARINI NM, Rosenkranz GK, Jaki T, Konig F, et al
    Subgroup identification in clinical trials via the predicted individual treatment effect.
    PLoS One. 2018;13:e0205971.
    PubMed     Abstract available


  180. MAUGHAM ML, Seim I, Thomas PB, Crisp GJ, et al
    No effect of unacylated ghrelin administration on subcutaneous PC3 xenograft growth or metabolic parameters in a Rag1-/- mouse model of metabolic dysfunction.
    PLoS One. 2018;13:e0198495.
    PubMed     Abstract available


  181. STRANDBERG S, Hashemi A, Axelsson J, Riklund K, et al
    Optimization of PET reconstruction algorithm, SUV thresholding algorithm and PET acquisition time in clinical 11C-acetate PET/CT.
    PLoS One. 2018;13:e0209169.
    PubMed     Abstract available


  182. HAMMES J, Hohberg M, Tager P, Wild M, et al
    Uptake in non-affected bone tissue does not differ between [18F]-DCFPyL and [68Ga]-HBED-CC PSMA PET/CT.
    PLoS One. 2018;13:e0209613.
    PubMed     Abstract available


    January 2017
  183. SEO Y, Ryu K, Park J, Jeon DK, et al
    Inhibition of ANO1 by luteolin and its cytotoxicity in human prostate cancer PC-3 cells.
    PLoS One. 2017;12:e0174935.
    PubMed     Abstract available


  184. LE B, Powers GL, Tam YT, Schumacher N, et al
    Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer.
    PLoS One. 2017;12:e0174658.
    PubMed     Abstract available


  185. LYNCH SM, Mitra N, Ross M, Newcomb C, et al
    A Neighborhood-Wide Association Study (NWAS): Example of prostate cancer aggressiveness.
    PLoS One. 2017;12:e0174548.
    PubMed     Abstract available


  186. FAN CY, Huang WY, Lin CS, Su YF, et al
    Risk of second primary malignancies among patients with prostate cancer: A population-based cohort study.
    PLoS One. 2017;12:e0175217.
    PubMed     Abstract available



  187. Correction: Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort.
    PLoS One. 2017;12:e0175606.
    PubMed     Abstract available


  188. PANG KH, Rosario DJ, Morgan SL, Catto JW, et al
    Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies.
    PLoS One. 2017;12:e0175070.
    PubMed     Abstract available


  189. ROHENA-RIVERA K, Sanchez-Vazquez MM, Aponte-Colon DA, Forestier-Roman IS, et al
    IL-15 regulates migration, invasion, angiogenesis and genes associated with lipid metabolism and inflammation in prostate cancer.
    PLoS One. 2017;12:e0172786.
    PubMed     Abstract available


  190. MARTINEZ-MARIN D, Jarvis C, Nelius T, de Riese W, et al
    PEDF increases the tumoricidal activity of macrophages towards prostate cancer cells in vitro.
    PLoS One. 2017;12:e0174968.
    PubMed     Abstract available


  191. ONUKWUGHA E, Kwok Y, Ciezki JP, Yong C, et al
    Skeletal-related events and mortality among men diagnosed with advanced prostate cancer: The impact of alternative measures of radiation to the bone.
    PLoS One. 2017;12:e0175956.
    PubMed     Abstract available


  192. AL AAMERI RFH, Sheth S, Alanisi EMA, Borse V, et al
    Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol.
    PLoS One. 2017;12:e0177198.
    PubMed     Abstract available


  193. OKEYO-OWUOR T, Benesh E, Bibbey S, Reid M, et al
    Exposure to maternal obesogenic diet worsens some but not all pre-cancer phenotypes in a murine genetic model of prostate cancer.
    PLoS One. 2017;12:e0175764.
    PubMed     Abstract available


  194. SCHUBERT C, Waletzko O, Weiss C, Voelzke D, et al
    Intercenter validation of a knowledge based model for automated planning of volumetric modulated arc therapy for prostate cancer. The experience of the German RapidPlan Consortium.
    PLoS One. 2017;12:e0178034.
    PubMed     Abstract available


  195. TENNILL TA, Gross ME, Frieboes HB
    Automated analysis of co-localized protein expression in histologic sections of prostate cancer.
    PLoS One. 2017;12:e0178362.
    PubMed     Abstract available


  196. DELOBEL JB, Gnep K, Ospina JD, Beckendorf V, et al
    Nomogram to predict rectal toxicity following prostate cancer radiotherapy.
    PLoS One. 2017;12:e0179845.
    PubMed     Abstract available


  197. RIVERA M, Ramos Y, Rodriguez-Valentin M, Lopez-Acevedo S, et al
    Targeting multiple pro-apoptotic signaling pathways with curcumin in prostate cancer cells.
    PLoS One. 2017;12:e0179587.
    PubMed     Abstract available


  198. ZEDAN AH, Blavnsfeldt SG, Hansen TF, Nielsen BS, et al
    Heterogeneity of miRNA expression in localized prostate cancer with clinicopathological correlations.
    PLoS One. 2017;12:e0179113.
    PubMed     Abstract available


  199. PASHAEI E, Pashaei E, Ahmady M, Ozen M, et al
    Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.
    PLoS One. 2017;12:e0179543.
    PubMed     Abstract available


  200. ROY A, Ramalinga M, Kim OJ, Chijioke J, et al
    Multiple roles of RARRES1 in prostate cancer: Autophagy induction and angiogenesis inhibition.
    PLoS One. 2017;12:e0180344.
    PubMed     Abstract available


  201. POLANEC SH, Andrzejewski P, Baltzer PAT, Helbich TH, et al
    Multiparametric [11C]Acetate positron emission tomography-magnetic resonance imaging in the assessment and staging of prostate cancer.
    PLoS One. 2017;12:e0180790.
    PubMed     Abstract available


  202. ZHANG Y, Su X, Kong Z, Fu F, et al
    An androgen reduced transcript of LncRNA GAS5 promoted prostate cancer proliferation.
    PLoS One. 2017;12:e0182305.
    PubMed     Abstract available


  203. ENDT K, Goepfert J, Omlin A, Athanasiou A, et al
    Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer.
    PLoS One. 2017;12:e0181557.
    PubMed     Abstract available


  204. ZHANG ZH, Xie DD, Xu S, Xia MZ, et al
    Total glucosides of paeony inhibits lipopolysaccharide-induced proliferation, migration and invasion in androgen insensitive prostate cancer cells.
    PLoS One. 2017;12:e0182584.
    PubMed     Abstract available


  205. WANG K, Jin S, Fan D, Wang M, et al
    Anti-proliferative activities of finasteride in benign prostate epithelial cells require stromal fibroblasts and c-Jun gene.
    PLoS One. 2017;12:e0172233.
    PubMed     Abstract available


  206. SUMIDA I, Yamaguchi H, Das IJ, Anetai Y, et al
    Robust plan optimization using edge-enhanced intensity for intrafraction organ deformation in prostate intensity-modulated radiation therapy.
    PLoS One. 2017;12:e0173643.
    PubMed     Abstract available


  207. ZHAN W, Gedroyc W, Xu XY
    The effect of tumour size on drug transport and uptake in 3-D tumour models reconstructed from magnetic resonance images.
    PLoS One. 2017;12:e0172276.
    PubMed     Abstract available


  208. LI SL, Ye Y, Yuan XH
    Association between Allogeneic or Autologous Blood Transfusion and Survival in Patients after Radical Prostatectomy: A Systematic Review and Meta-Analysis.
    PLoS One. 2017;12:e0171081.
    PubMed     Abstract available


  209. ZHOU J, Gao S, Hsieh CL, Malla M, et al
    Peptide B targets soluble guanylyl cyclase alpha1 and kills prostate cancer cells.
    PLoS One. 2017;12:e0184088.
    PubMed     Abstract available


  210. LUCAS JL, Tacheny EA, Ferris A, Galusha M, et al
    Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy.
    PLoS One. 2017;12:e0182739.
    PubMed     Abstract available


  211. CANESIN G, Evans-Axelsson S, Hellsten R, Krzyzanowska A, et al
    Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.
    PLoS One. 2017;12:e0184418.
    PubMed     Abstract available


  212. GUI B, Hsieh CL, Kantoff PW, Kibel AS, et al
    Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer.
    PLoS One. 2017;12:e0184166.
    PubMed     Abstract available


  213. READY D, Yagiz K, Amin P, Yildiz Y, et al
    Mapping the STK4/Hippo signaling network in prostate cancer cell.
    PLoS One. 2017;12:e0184590.
    PubMed     Abstract available



  214. Correction: Evaluation of different mathematical models and different b-value ranges of diffusion-weighted imaging in peripheral zone prostate cancer detection using b-value up to 4500 s/mm2.
    PLoS One. 2017;12:e0184609.
    PubMed     Abstract available


  215. LIAO JM, Ommerborn MJ, Clark CR
    Association between features of patient-provider discussions and routine prostate-specific antigen testing.
    PLoS One. 2017;12:e0177687.
    PubMed     Abstract available


  216. KARLSSON J, Gouveia-Figueira S, Alhouayek M, Fowler CJ, et al
    Effects of tumour necrosis factor alpha upon the metabolism of the endocannabinoid anandamide in prostate cancer cells.
    PLoS One. 2017;12:e0185011.
    PubMed     Abstract available


  217. SOUZA MF, Kuasne H, Barros-Filho MC, Ciliao HL, et al
    Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer.
    PLoS One. 2017;12:e0184094.
    PubMed     Abstract available


  218. KANG M, Lee KH, Lee HS, Jeong CW, et al
    Concurrent treatment with simvastatin and NF-kappaB inhibitor in human castration-resistant prostate cancer cells exerts synergistic anti-cancer effects via control of the NF-kappaB/LIN28/let-7 miRNA signaling pathway.
    PLoS One. 2017;12:e0184644.
    PubMed     Abstract available


  219. OPOKU-ACHEAMPONG AB, Henningson JN, Beck AP, Lindshield BL, et al
    5alpha-reductase 1 mRNA levels are positively correlated with TRAMP mouse prostate most severe lesion scores.
    PLoS One. 2017;12:e0175874.
    PubMed     Abstract available


  220. LUO Q, Egger S, Yu XQ, Smith DP, et al
    Validity of using multiple imputation for "unknown" stage at diagnosis in population-based cancer registry data.
    PLoS One. 2017;12:e0180033.
    PubMed     Abstract available


  221. LAISECA JE, Ladelfa MF, Cotignola J, Peche LY, et al
    Functional interaction between co-expressed MAGE-A proteins.
    PLoS One. 2017;12:e0178370.
    PubMed     Abstract available


  222. ZLITNI A, Yin M, Janzen N, Chatterjee S, et al
    Development of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry.
    PLoS One. 2017;12:e0176958.
    PubMed     Abstract available


  223. STROMVALL K, Thysell E, Halin Bergstrom S, Bergh A, et al
    Aggressive rat prostate tumors reprogram the benign parts of the prostate and regional lymph nodes prior to metastasis.
    PLoS One. 2017;12:e0176679.
    PubMed     Abstract available


  224. ZHAO A, Chen F, Ning C, Wu H, et al
    Use of real-time cellular analysis and Plackett-Burman design to develop the serum-free media for PC-3 prostate cancer cells.
    PLoS One. 2017;12:e0185470.
    PubMed     Abstract available


  225. ROUVIERE O, Dagonneau T, Cros F, Bratan F, et al
    Diagnostic value and relative weight of sequence-specific magnetic resonance features in characterizing clinically significant prostate cancers.
    PLoS One. 2017;12:e0178901.
    PubMed     Abstract available


  226. REULEN RC, de Vogel S, Zhong W, Zhong Z, et al
    Physical activity and risk of prostate and bladder cancer in China: The South and East China case-control study on prostate and bladder cancer.
    PLoS One. 2017;12:e0178613.
    PubMed     Abstract available


  227. YU EJ, Hooker E, Johnson DT, Kwak MK, et al
    LZTS2 and PTEN collaboratively regulate ss-catenin in prostatic tumorigenesis.
    PLoS One. 2017;12:e0174357.
    PubMed     Abstract available


  228. KHAN S, Simpson J, Lynch JC, Turay D, et al
    Racial differences in the expression of inhibitors of apoptosis (IAP) proteins in extracellular vesicles (EV) from prostate cancer patients.
    PLoS One. 2017;12:e0183122.
    PubMed     Abstract available


  229. ROBLES-FERNANDEZ I, Martinez-Gonzalez LJ, Pascual-Geler M, Cozar JM, et al
    Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness.
    PLoS One. 2017;12:e0185447.
    PubMed     Abstract available


  230. MURPHY C, Rettedal E, Lehouritis P, Devoy C, et al
    Intratumoural production of TNFalpha by bacteria mediates cancer therapy.
    PLoS One. 2017;12:e0180034.
    PubMed     Abstract available


  231. THON A, Teichgraber U, Tennstedt-Schenk C, Hadjidemetriou S, et al
    Computer aided detection in prostate cancer diagnostics: A promising alternative to biopsy? A retrospective study from 104 lesions with histological ground truth.
    PLoS One. 2017;12:e0185995.
    PubMed     Abstract available


  232. MORLANDO M, Pelullo CP, Di Giuseppe G
    Prostate cancer screening: Knowledge, attitudes and practices in a sample of men in Italy. A survey.
    PLoS One. 2017;12:e0186332.
    PubMed     Abstract available


  233. LEAPMAN MS, Westphalen AC, Ameli N, Lawrence HJ, et al
    Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa).
    PLoS One. 2017;12:e0185535.
    PubMed     Abstract available


  234. ARTHURS C, Murtaza BN, Thomson C, Dickens K, et al
    Expression of ribosomal proteins in normal and cancerous human prostate tissue.
    PLoS One. 2017;12:e0186047.
    PubMed     Abstract available


  235. HEBBRECHT T, Van Audenhove I, Zwaenepoel O, Verhelle A, et al
    VCA nanobodies target N-WASp to reduce invadopodium formation and functioning.
    PLoS One. 2017;12:e0185076.
    PubMed     Abstract available


  236. AL-MAHROUKI A, Giles A, Hashim A, Kim HC, et al
    Microbubble-based enhancement of radiation effect: Role of cell membrane ceramide metabolism.
    PLoS One. 2017;12:e0181951.
    PubMed     Abstract available


  237. XIAO WJ, Zhu Y, Dai B, Ye DW, et al
    Evaluation of the major changes in eighth edition of the American Joint Committee on Cancer pathological staging for prostate cancer treated with prostatectomy.
    PLoS One. 2017;12:e0187887.
    PubMed     Abstract available


  238. TAUROZZI AJ, Beekharry R, Wantoch M, Labarthe MC, et al
    Spontaneous development of Epstein-Barr Virus associated human lymphomas in a prostate cancer xenograft program.
    PLoS One. 2017;12:e0188228.
    PubMed     Abstract available


  239. JEON HG, Yoo JH, Jeong BC, Seo SI, et al
    Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance.
    PLoS One. 2017;12:e0186026.
    PubMed     Abstract available


  240. ANDERSEN S, Richardsen E, Rakaee M, Bertilsson H, et al
    Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.
    PLoS One. 2017;12:e0189000.
    PubMed     Abstract available


  241. PASQUIER D, Nickers P, Peiffert D, Maingon P, et al
    Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO).
    PLoS One. 2017;12:e0187794.
    PubMed     Abstract available


  242. ABDEL-RAHMAN O
    Assessment of the prognostic value of the 8th AJCC staging system for patients with clinically staged prostate cancer; A time to sub-classify stage IV?
    PLoS One. 2017;12:e0188450.
    PubMed     Abstract available


  243. JAMES LJ, Wong G, Craig JC, Hanson CS, et al
    Men's perspectives of prostate cancer screening: A systematic review of qualitative studies.
    PLoS One. 2017;12:e0188258.
    PubMed     Abstract available


  244. VONDALOVA BLANAROVA O, Safarikova B, Herudkova J, Krkoska M, et al
    Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10.
    PLoS One. 2017;12:e0188584.
    PubMed     Abstract available


  245. STROMVALL K, Lundholm M, Thysell E, Bergh A, et al
    Highly aggressive rat prostate tumors rapidly precondition regional lymph nodes for subsequent metastatic growth.
    PLoS One. 2017;12:e0187086.
    PubMed     Abstract available


  246. JEDROSZKA D, Orzechowska M, Hamouz R, Gorniak K, et al
    Markers of epithelial-to-mesenchymal transition reflect tumor biology according to patient age and Gleason score in prostate cancer.
    PLoS One. 2017;12:e0188842.
    PubMed     Abstract available


  247. RICHARDSEN E, Andersen S, Al-Saad S, Rakaee M, et al
    Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort.
    PLoS One. 2017;12:e0186852.
    PubMed     Abstract available


  248. KOO K, Brackett CD, Eisenberg EH, Kieffer KA, et al
    Impact of numeracy on understanding of prostate cancer risk reduction in PSA screening.
    PLoS One. 2017;12:e0190357.
    PubMed     Abstract available


  249. EINELUOTO JT, Jarvinen P, Kenttamies A, Kilpelainen TP, et al
    Repeat multiparametric MRI in prostate cancer patients on active surveillance.
    PLoS One. 2017;12:e0189272.
    PubMed     Abstract available


  250. DENSLOW A, Switalska M, Jarosz J, Papiernik D, et al
    Clopidogrel in a combined therapy with anticancer drugs-effect on tumor growth, metastasis, and treatment toxicity: Studies in animal models.
    PLoS One. 2017;12:e0188740.
    PubMed     Abstract available


    January 2016
  251. APRELIKOVA O, Tomlinson CC, Hoenerhoff M, Hixon JA, et al
    Development and Preclinical Application of an Immunocompetent Transplant Model of Basal Breast Cancer with Lung, Liver and Brain Metastases.
    PLoS One. 2016;11:e0155262.
    PubMed     Abstract available


  252. MASOOMPOUR SM, Lankarani KB, Honarvar B, Tabatabaee SH, et al
    Changing Epidemiology of Common Cancers in Southern Iran, 2007-2010: A Cross Sectional Study.
    PLoS One. 2016;11:e0155669.
    PubMed     Abstract available


  253. ONER C, Turgut Cosan D, Colak E
    Estrogen and Androgen Hormone Levels Modulate the Expression of PIWI Interacting RNA in Prostate and Breast Cancer.
    PLoS One. 2016;11:e0159044.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: